Healthcare and Life Sciences Q1 2023 Review: IPOs and SPACs

by May 3, 2023Analysis, Funding

Biopharma IPOs as Investors Bet On Life-Saving Breakthroughs

Only $400 million in 3 newly filed IPOs were raised in Q1 2023 – 1 fewer IPO filing compared to Q4 2022 but with a slightly higher value vs. $300 million raised in Q4 2022.

Q2 of 2021 saw the most significant number of IPO filings, resulting in a total amount raised of $12.6 billion. However, certain companies had to withdraw their IPO filings due to extended timelines from the first filing and adverse market conditions.


SPAC IPO Activity - Global Healthcare and Life Sciences

In Q1 of 2023, there were merely 2 SPAC IPO filings, raising $100 million. However, the healthcare and life sciences sector experienced no notable growth since Q4 of 2021, which saw 26 SPAC IPOs raising $4.3 billion. The industry’s most significant fund generation was in Q1 of 2021, with 39 SPAC IPO filings and $11.8 billion raised.


IPO Filings – Q1 2023
  • CytoMed Therapeutics Limited, a preclinical biopharmaceutical company focused on developing novel cell-based immunotherapies for cancer treatment, priced its IPO of 2,412,369 ordinary shares at $4.00 per share for gross proceeds of $9,649,476. The company granted underwriters an option to purchase 361,855 ordinary shares to cover over-allotments. The shares are expected to trade on Nasdaq as “GDTC” The offering is set to close on April 18, 2023.
  • TransCode Therapeutics, Inc. has signed a deal with investor White Lion Capital, LLC, to sell up to $1.08 million of its common stock until May 31, 2023, for working capital and general corporate purposes. TransCode specializes in developing RNA therapeutics for cancer, focusing on glioblastoma and other difficult-to-treat cancers.

🔒 DealForma customers: Search for all IPOs


Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Venture Activity In Global Healthcare & Life Sciences – 2023

Venture Activity In Global Healthcare & Life Sciences – 2023

An increase in down rounds in 2023 indicates a reassessment of valuations in VC. Challenges are expected to persist in the sector through the H1 of 2024, grappling with repercussions from previous excesses and a challenging fundraising environment. The initiation of a...